Literature DB >> 8469932

Low prevalence of complement deficiencies among patients with meningococcal disease in Norway.

K Høgåsen1, T Michaelsen, O J Mellbye, G Bjune.   

Abstract

Sera from 98 individuals who had survived meningococcal disease were analysed for classical and alternative pathway haemolytic activity and the complement components C3, C4 and properdin. No complete deficiency was found. However, median properdin concentration was only 86% in the disease group compared with the controls (P < 0.001). Properdin was also significantly lower in serogroup C disease (median 76%) compared with serogroup B disease (median 90%, P = 0.005). Severe properdin deficiency is an established risk factor for meningococcal disease. The present data may indicate that even moderately reduced properdin level can increase the risk of developing meningococcal disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8469932     DOI: 10.1111/j.1365-3083.1993.tb03323.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  9 in total

1.  Reference distributions for complement proteins C3 and C4: a comparison of a large cohort to the world's literature.

Authors:  Robert F Ritchie; Glenn E Palomaki; Louis M Neveux; Olga Navolotskaia
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

2.  Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial.

Authors:  E Wedege; E A Høiby; E Rosenqvist; G Bjune
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

Review 3.  Update on meningococcal disease with emphasis on pathogenesis and clinical management.

Authors:  M van Deuren; P Brandtzaeg; J W van der Meer
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

4.  Primary immunodeficiency diseases in Norway.

Authors:  A Stray-Pedersen; T G Abrahamsen; S S Frøland
Journal:  J Clin Immunol       Date:  2000-11       Impact factor: 8.317

5.  Relationships Between Clinico-Epidemiological Patterns of Invasive Meningococcal Infections and Complement Deficiencies in French South Pacific Islands (New Caledonia).

Authors:  Maguy Daures; Michele John; Cécile Veysseyre Balter; Olivier Simon; Yann Barguil; Isabelle Missotte; Jean-Paul Grangeon; Sylvie Laumond-Barny; Martine Noel; Laurent Besson-Leaud; Pierre-Emmanuel Spasic; Aurélie de Suremain; Ann-Claire Gourinat; Elodie Descloux
Journal:  J Clin Immunol       Date:  2014-10-29       Impact factor: 8.317

6.  Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine.

Authors:  E Rosenqvist; E A Høiby; E Wedege; K Bryn; J Kolberg; A Klem; E Rønnild; G Bjune; H Nøkleby
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

7.  Long-term mortality in patients diagnosed with meningococcal disease: a Danish nationwide cohort study.

Authors:  Casper Roed; Lars Haukali Omland; Frederik Neess Engsig; Peter Skinhoj; Niels Obel
Journal:  PLoS One       Date:  2010-03-12       Impact factor: 3.240

8.  Complement activation in relation to capillary leakage in children with septic shock and purpura.

Authors:  J A Hazelzet; R de Groot; G van Mierlo; K F Joosten; E van der Voort; A Eerenberg; M H Suur; W C Hop; C E Hack
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

9.  Meningococcal disease: changes in epidemiology and prevention.

Authors:  Qiuzhi Chang; Yih-Ling Tzeng; David S Stephens
Journal:  Clin Epidemiol       Date:  2012-09-19       Impact factor: 4.790

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.